Bio-Path's Plan to Develop Liposomal Grb-2 as a Targeted Therapy Against Inflammatory Breast Cancer and Triple Negative Breast Cancer

"...Focusing on its longer-term pipeline, the Company announced it is initiating development of its lead cancer drug BP-100-1.01 (Liposomal Grb-2) to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates. Bio-Path’s plan is to develop Liposomal Grb-2 as a targeted therapy against TNBC and IBC. Treatment goals are two-pronged: the first being to develop Liposomal Grb-2 as a tumor reduction agent in combination with other approved drugs in pre-operative settings, and the second is to develop Liposomal Grb-2 as a drug to treat and control or eliminate cancer metastasis in TNBC and IBC patients. Both of these treatment goals address high need situations for patients..."

UPDATE July 22, 2013- "It is expected that after the completion of pre-clinical studies, a Phase I clinical trial in TNBC and IBC will be initiated by Bio- Path Holdings Inc. in 2014."
http://bionews-tx.com/news/2013/07/22/bio-path-holdings-initiates-development-of-liposomal-grb-2-for-triple-negative-and-inflammatory-breast-cancers/ (Click link to story)


http://www.rxir.com/SSI/ClientPR/201324102455.shtml (Link to story)

http://bionews-tx.com/news/2013/04/04/bio-path-holdings-expands-reach-of-non-toxic-md-anderson-tested-cancer-treatment/ (Link to story)

http://finance.yahoo.com/news/bio-path-shares-attractive-now-153340813.html (Link to story)

http://seekingalpha.com/instablog/685353-grant-zeng/1572271-bio-path-shares-are-attractive-now (Link to story)